Uy, G L <br/><br/>
Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.  [electronic resource] 

 -  Bone marrow transplantation  May 2009 
 - 793-800 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5365 
<br/><br/><label>Standard No.: </label>10.1038/bmt.2008.384  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Female<br/>Granulocyte Colony-Stimulating Factor--administration & dosage<br/>Hematopoietic Stem Cell Mobilization<br/>Herpesvirus 3, Human--drug effects<br/>Humans<br/>Killer Cells, Natural--drug effects<br/>Lymphocyte Subsets<br/>Male<br/>Melphalan--administration & dosage<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Peripheral Blood Stem Cell Transplantation--methods<br/>Pyrazines--administration & dosage<br/>Remission Induction<br/>Survival Analysis<br/>T-Lymphocytes, Cytotoxic--drug effects<br/>Transplantation, Autologous<br/>Treatment Outcome<br/>Virus Activation--drug effects